Merck

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Merck and other ETFs, options, and stocks.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other.

CEO

Robert M. Davis

CEORobert M. Davis

Employees

72,000

Employees72,000

Headquarters

Rahway, New Jersey

HeadquartersRahway, New Jersey

Founded

1891

Founded1891

Employees

72,000

Employees72,000

MRK Key Statistics

Market cap

317.41B

Market cap317.41B

Price-Earnings ratio

140.10

Price-Earnings ratio140.10

Dividend yield

2.42%

Dividend yield2.42%

Average volume

6.79M

Average volume6.79M

High today

$128.70

High today$128.70

Low today

$125.02

Low today$125.02

Open price

$126.93

Open price$126.93

Volume

6.47M

Volume6.47M

52 Week high

$134.63

52 Week high$134.63

52 Week low

$99.14

52 Week low$99.14

MRK News

Seeking Alpha 16h

Pfizer, Merck bladder cancer therapy endorsed for approval in EU

Merck (NYSE:MRK) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed its blockbuster anti-PD-1 therapy...

Benzinga 3d

Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants

On Tuesday, Merck & Co Inc MRK shared topline results from its Phase 2b/3 clinical trial (MK-1654-004) of clesrovimab (MK-1654). Clesrovimab is the company’s i...

Simply Wall St 4d

Merck & Co., Inc. is largely controlled by institutional shareholders who own 78% of the company

Key Insights Significantly high institutional ownership implies Merck's stock price is sensitive to their trading actions 45% of the business is held by the t...

Analyst ratings

82%

of 28 ratings

Buy

82.1%

Hold

17.9%

Sell

More MRK News

Seeking Alpha 4d

Merck RSV therapy succeeds in infants in challenge to Sanofi, Astra

Merck (NYSE:MRK) on Tuesday announced plans to seek regulatory clearance for its experimental therapy Clesrovimab to prevent respiratory syncytial virus (RSV) d...